NCT02263040View on ClinicalTrials.gov

A Pilot Study to Assess the Immunogenicity and Reactogenicity of High Versus Standard Dose TIV

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

July 31, 2016

Study Completion Date

December 31, 2016

Conditions
Influenza
Interventions
BIOLOGICAL

Fluzone High-Dose

Influenza vaccine

BIOLOGICAL

Fluzone (standard dose)

Influenza vaccine

Trial Locations (1)

M5G 1X5

Mount Sinai Hospital, Toronto

All Listed Sponsors
lead

Mount Sinai Hospital, Canada

OTHER

NCT02263040 - A Pilot Study to Assess the Immunogenicity and Reactogenicity of High Versus Standard Dose TIV | Biotech Hunter | Biotech Hunter